Drugs / Polatuzumab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04739813 | Jul 2021 → May 2026 overdue | Burkitt lymphoma, diffuse large B-cell lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06765317 | Jan 2025 → Jan 2028 expected | high grade B-cell lymphoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05800366 | Apr 2023 → Sep 2026 expected | diffuse large B-cell lymphoma | Jennifer Crombie, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05260957 | Dec 2022 → Dec 2026 expected | non-Hodgkin lymphoma | Lazaros Lekakis | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07371923 Background | Nov 2025 → Feb 2028 expected | diffuse large B-cell lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polatuzumab | “zanubrutinib combined with Pola-R-CHP regimen: zanubrutinib 160mg bid d1-d21/C1-C6; polatuzumab 1.8mg/kg d1/C1-C6; rituximab 375mg/㎡, iv, d1/C1-C6; cyclophosphamide 750mg/㎡,...” NCT07371923 ↗ |
| Modality | Monoclonal antibody | “an antibody drug conjugate (ADC) that contains a humanized IgG1 anti-human CD79b monoclonal antibody, via IV infusion” NCT05800366 ↗ |
| Route | Intravenous | “administered intravenously” NCT04739813 ↗ |
| Target | CD79B | “anti-mitotic antibody-drug conjugate targeting CD79b, polatuzumab” NCT04739813 ↗ |